Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis
Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis
Quest PharmaTech Inc. 表示 Oregovomab 三期臨床研究未能通過徒勞性分析
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊